Skip to main content
Jack HU

Jack HU, Not Applicable

CEO, Calissa Therapeutics
United States
Dr. Jack Hu, founder and CEO of Calissa Therapeutics, leverages his extensive experience in finance and biopharma to develop and commercialize a first-in-class therapy for birthmarks and rosacea. Prior to founding Calissa, Dr. Hu served as CFO and CSO of Genor Biopharma, where he raised $560 million in IPO/crossover, and transformed company's pipeline through strategic business development deals. During his earlier career on Wall Street at both buyside and sellside, he was a biotech analyst with Leerink Partners and Oppenheimer, and a Managing Director with Deutsche Bank covering APAC healthcare where he was ranked no.1 by institutional investor. He started his career at Wyeth Biopharma as a marketing manager, and was trained at the University of Texas M.D. Anderson Cancer Center.

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.